Innate Pharma SA (OTCMKTS:IPHYF) Short Interest Up ∞ in May

Innate Pharma SA (OTCMKTS:IPHYF) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 23,016 shares, a growth of ∞ from the April 30th total of 0 shares. Based on an average daily volume of 36 shares, the short-interest ratio is currently 639.3 days. Currently, 0.0% of the shares of the company are sold short.

Innate Pharma Stock Performance

Shares of IPHYF stock opened at $1.65 on Wednesday. Innate Pharma has a 12-month low of $1.37 and a 12-month high of $2.25. The firm’s 50 day moving average is $1.62 and its 200 day moving average is $1.94.

About Innate Pharma

Innate Pharma is a clinical-stage biotechnology company headquartered in Marseille, France, focused on harnessing the innate immune system to develop novel immunotherapies for oncology and inflammatory diseases. Founded in 1999, the company applies its expertise in natural killer (NK) cell and macrophage biology to design antibodies and other biologic agents that modulate immune checkpoints and enhance antitumor responses.

The company’s pipeline includes several lead programs such as monalizumab, an anti-NKG2A antibody designed to restore NK cell and CD8+ T cell activity, and lirilumab, which targets KIR receptors on NK cells to promote tumor cell killing.